Focus on "Anti -Tumor State, Casting Hope" MDT Summit Forum, and see the strong return of the two major domestic anti -tumor products!

*For medical professionals for reading reference

The summit forum focuses on the two major anti -tumor products of Nepalese injection and Baidian injection, and the current status and prospects of the clinical application of the central nervous system and hemorrhoid tumors.

On June 18, 2022, the "Anti -Tumor Xiangbang, co -organized by the China Anti -Cancer Association, the Beijing Oncology Society of the Beijing Oncology Society, co -organized by the" medical community "and online live broadcast, China Resources Shuanghe Pharmaceutical Co., Ltd. Hope "Central nervous system and hematological tumor MDT Summit Forum -Beijing -Tianjin -Hebei special session, which is grandly held in an online meeting. With the unremitting efforts of China Resources Shuanghe Pharmaceutical Co., Ltd., this Summit Forum focuses on the two major anti -tumor products in the domestic market in the spring of 2022 to return to the domestic market. The current status and prospects of blood tumors.

Professor Yang Xuejun, Beijing Chang Geng Hospital, Tsinghua University, Professor Jiang Erlie, Hematology Hospital of the Chinese Academy of Medical Sciences, Professor Jiao Baohua, the Second Affiliated Hospital of Hebei Medical University, and Professor Wang Xiaoling of Beijing Children's Hospital affiliated to the Capital Medical University. In addition, more than 20 experts from well -known medical institutions from the Chinese Academy of Medical Sciences, Beijing Union Hospital, Beijing Children's Hospital, Hebei Provincial People's Hospital, Tianjin Cancer Hospital and other well -known domestic medical institutions are invited to speakers or discussing guests The identity was invited to participate in this summit forum, and the clinical application and latest research of Nepalese and Bai Lian'an together brought a wonderful academic feast.

In the opening speech, Professor Yang Xuejun, chairman of the forum and neurosurgeon expert, said: "Our old doctors have a complex for Nepalese. When they start to participate in clinical work in the early 1990s, the treatment of the central nervous system and the blood system for the treatment of the central nervous system and the blood system The drug of the tumor is still very scarce. For Nepalese is one of the optional drugs, and its successful domestic and return to the market is also a good thing for the treatment of central nervous system and blood system tumor treatment. It will provide us with more Treatment weapons and solutions. "

Professor Jiang Erlie, a hematology expert who co -worked as the chairman of the forum, pointed out in his speech: "Whether it is autologous or foreign body hematopoietic stem cell transplantation, Bai Lian'an is the cornerstone of pre -treatment before transplantation, but in the past, there has been no domestic version of Bai Lian'an listing. After the confession was broken, the clinical stall appeared. Shuanghe Pharmaceutical Bai Liannian injection was listed, which successfully filled this gap, which is expected to benefit more patients in my country. I hope to deepen the academic colleagues in China through the academic discussions of this summit forum. Cognition and use level. "

Professor Jiao Baohua, chairman of the forum engaged in the central nervous system malignant tumor surgery treatment: "The treatment of malignant tumors in the central nervous system has entered the era of multidisciplinary diagnosis (MDT), which has been comprehensively used in surgery, chemotherapy, radiotherapy, and targeted therapy, but Due to the difficulty of penetrating the blood -brain barrier, the chemotherapy drugs that can be used in the past are very limited. Nepalese -sarcinoside with small molecular weight and high fat -soluble can achieve the purpose of treatment. Its regression will also bring new hopes for patients in my country. "

Professor Wang Xiaoling, who deeply cultivates clinical pharmacy, believes: "Clinical necessity or important drugs, especially the guidelines required for children with hematological tumor patients, and irreplaceable 'life -saving medicines' disconnection, which brings great greatness to clinical work. The difficulties, so domestic pharmaceutical companies need courage and responsibility, so that more clinical drugs must be dominated by drugs. For this reason, all parties are constantly working hard. The market. In the era when the evidence is king and the data is king, our pharmacy department will also participate in the test of clinical practice and strive to verify the treatment value of domestic drugs. "

"As one of the 15 special actions of the health China strategy, the prevention and treatment of malignant tumors has risen to the national strategy, but there are still many cancer patients in China to endure the pain of not buying 'life -saving medicines. Ethnic pharmaceutical companies, we have the responsibility, obligations to contribute to the clinical and the well -being of the majority of patients. In the crisis of crisis in the clinical disconnection of Nepalese and Bailian, we break through various technical difficulties such as imported drug crafts. The re -production and research and development of the two drugs lasted for 5 years for Nepalin, and Bai Lian'an lasted for 8 years. Finally, they met with doctors and patients with a new look. With the clinical exploration and application of the two drugs in the future, they It will bring the hope of long -term survival to more patients, "said Ms. Li Ning, general manager of China Resources Shuanghe Beijing Business Department.

Fighting a variety of tumors is still an indispensable choice for Nepaleitin

The first invited speaker -Professor Professor of Tsinghua Chang Geng Hospital, Tsinghua University, a special report on the application of Nepalinyin's treatment in central nervous system tumor treatment. He emphasized that, as a kind of ghost toxin derivative drug, Nepaleitin is a inhibitor of the topological isoidase II. The action mechanism is similar to that of similar drugs. The advantages of blood and brain barrier, so it has better central permeability, which is suitable for the treatment of brain metastases of brain metastases of brain gum tumors and other malignant tumors.

In terms of treating primary central nervous system tumors, domestic guidelines such as "Chinese central nervous system gel tumor diagnosis and therapy" (2015 edition) and other domestic guides are currently recognized as high -grade gum tumors and low -level gum. One of the optional chemotherapy drugs such as tumors and other patients. Some pre -clinical studies have shown that Nepaleitin has a significant inhibitory effect on gel tumors that exist in IDH mutations; and many clinical studies at home and abroad have also showed that the use of Nepalinininin or other chemotherapy drugs can improve glue quality Survival of patients with tumor. In terms of treating malignant tumor brain metastases, taking lung cancer with a higher incidence in my country as an example, whether it is non -small cell lung cancer (NSCLC) or small cell lung cancer (SCLC), the risk of brain metastases in patients is high. treat. Nepalese -Nepisyl's similar drugs are currently an important part of the SCLC's first -line treatment plan, and domestic clinical studies have shown that Nepalese single drugs or combined with platinum chemotherapy and radiotherapy are used. The effect of the treatment of brain metastases is similar to that of Potidoside, and the overall safety is good.

Professor Zhao Jie of the Aerospace Center Hospital reported on the title of "Application of Nepalese in Pymosis and Transplantation Pre -treatment". She pointed out that for patients with acute lymphocyte leukemia (ALL) Some components of chemotherapy schemes play a role in inducing treatment, post -relief treatment, and early prevention of leukemia (CNSL) such as centered nervous system. It is expected to turn into the advantage of clinical treatment.

A number of clinical studies at home and abroad show that multi -drug combined chemotherapy schemes containing Nepalese are not only comparable to other commonly used chemotherapy schemes in terms of overall efficacy. Patients with CNS is more l are for patients with Nepalidin, and patients with low littering recurrence of CNS and have a good survival rate of CNS metastasis in the baseline. Recommended medications; when used for acute myeloblast leukemia (AML), Nepalin can participate in the first -line induction scheme, and can also be used for the treatment of patients with relapse/refractory leukemia.

In terms of pre -processing before transplantation of patients, the latest clinical study carried out by Chinese scholars recently showed that the pre -treatment of Nepalese plants can be used for transplantation. Significant clinical benefits, 32 recurrence/refractory patients incorporated into the study, the 1 -year total survival (OS) rate (OS) rate (OS) rate for transplantation after receiving Nepalin was treated with Nepalin was 62.50%. The two -year leukemia survival (LFS) rates were 56.30%and 46.90%, respectively.

Professor Qian Zhengzi, Tianjin Cancer Hospital, introduced the value and application status of Nepalidin in the treatment of primary central nervous system lymphoma (PCNSL) treatment. She said that PCNSL is a rare non -Hodgkin lymphoma as a whole The patient's disease is limited to the central nervous system, and the overall prognosis is poor. Some data show that the 5 -year OS rate of patients with PCNSL patients is only about 30%. Chemotherapy is the main treatment method of the current clinical clinical.

Domestic and foreign guidelines are recommended to use large-dose methotrexate (HD-MTX) as the cornerstone of the first line of chemotherapy. It is composed of other chemotherapy drugs to form a "MTX+X" solution. For the process, and some patients cannot tolerate or are suitable for treatment, but napit-sully drugs or combined treatment are currently one of the optional treatment plans for patients with PCNSL patients, and they are expected to be used for patients who are not suitable for HD-MTX schemes. Essence

Looking at the retrospective research data from Huashan Hospital, Beijing Union Hospital affiliated to Fudan University, Beijing Union Hospital and other top domestic centers showed that the chemotherapy scheme (such as MBVP) with Nepalese and HD-MTX schemes are equivalent to the effect. A similar conclusion and a single drug or combined treatment for Nepalitin are better effective in the treatment of patients with initial treatment. The use of Nepalese-MTX for Nepalidin also shows a significant improvement of patients' survival. The focus of the next clinical exploration is not suitable for MTX treatment crowds, and the value of new types of therapy such as Nepalin-Nepalin combined with targeted therapy, immunotherapy, and CAR-T therapy should be evaluated.

The discussion session of the first half of the forum was chaired by Professor Yang Xuejun. Many participating experts focused on the clinical application of the central nervous system tumor, blood system tumor therapy, and the clinical application of Nepalidin.

Professor Ma Wenbin, Beijing Union Hospital: The treatment of physical tumors in the central nervous system is still very difficult. For example, patients with colloidal cytoma, the 5 -year survival rate in clinical research and real world is still less than 10%. Few, so it is very important to use the original cytotoxic drugs. The regression of Nepaleitin will be conducive to the choice of second -line treatment plan.

Professor Wanjinghai, Cancer Hospital of the Chinese Academy of Medical Sciences: There are many patients in the current clinical clinic, such as patients with gumocytoma who recur after the treatment of olizolid, and there are no patients with brain metastases who drive gene mutations. We wait and see for the launch of Nepaleitin. At the same time, clinical workers also need to better use drugs in the age of molecular pathology. In the future, we should further explore the joint use of other drugs and the management of side effects.

Professor Wang Jingbo of Aerospace Center Hospital: The effect of nytinoside is good and small. It was previously a common drug for tumor chemotherapy in the center of the center of the center of the center of the center of the center of the blood system. With the help of government departments and China Resources Shuanghe Pharmaceuticals, we have successfully obtained a number of drugs over the predicament. We look forward to more clinical research in the future and further expand the scope of the adaptation and guideline recommendation of Nepalese.

Professor Wang Xiaoguang of Tianjin Medical University Cancer Hospital: The ability to penetrate the blood -brain barrier has restricted the application of many chemotherapy drugs in the central nervous system tumor. The ability of Nepalin to be strong in this area is an important clinical advantage. In the future It is hoped that we can continue to improve on the current basis of Nepalidin, so that the drug's brain ability is stronger and the treatment effect is better.

Professor Liu Xiaomin of Tianjin Huanhu Hospital: The treatment of patients with central nervous system tumors should be used to achieve individualized treatment through the MDT model. Chemotherapy drugs such as Nepalin, and various treatments such as radiotherapy and surgery are organically combined to allow patients Benefit.

Professor Liu Lihong, Fourth Hospital of Hebei Medical University: For PCNSL patients with greater treatment, I look forward to seeing the clinical efficacy of Nepalinin combined with large dose MTX schemes. At the same time Polycin is expected to join the existing pre -processing plan before transplantation.

Professor Xue Xiaoying of the Second Hospital of Hebei Medical University: The treatment of central nervous system tumor treatment is currently facing too many dilemma. Compared with the treatment of extraterioxidth physical tumors, the existing treatment drugs still do not become a system. It is very exciting and hopes that there are random control research or real world data to facilitate clinicians to master their curative effects and safety.

Professor Li Feng of the Cancer Hospital of Shandong First Medical University: The current treatment effect of glue motherocytoma is still unsatisfactory. Surgery, chemotherapy, electric field treatment and other means, although the patient's median survival has been raised to about 20 months , But there is still a big gap with the expectations of doctors. It is hoped that the "old medicine and new use" can conduct related clinical research as soon as possible to guide clinical applications with results.

Professor Yang Xuejun pointed out in the summary speech of the first half of the Summit Forum: "The academic community is the vocalization of clinical essential drugs such as Nepalin, which can promote the reproduction of drugs, re -listing, and provide more weapons for clinical treatment. At the same time, this is also the central nervous system. The treatment of system tumors and blood system tumors uses another 'first year' for Nepalese, and I look forward to carrying out more related cooperation research. "

Bai Lian'an's "classic inheritance" journey

In the second half of the MDT Summit Forum, the classic drugs pre -treated before the transplantation of hematopoietic stem cells -Bai Lian'an Injecting fluid was launched. Professor He Yi of the Hematology Hospital of the Chinese Academy of Medical Sciences first introduced the current status of Bai Lian'an. She believes that the value of hematopoietic stem cell transplantation is beyond doubt that the value of the treatment of malignant hematological diseases is undoubted. The number of transplants in my country is also rising every year. The level of management and academic achievements gradually approach the world. Successful central link.

Bai Lian'an is a key drug in the pre -processing link in my country's clinical practice. Its combined cyclopingamide scheme is one of the classic clinical schemes. Many clinical studies have shown that a variety of combined pre -treatment programs treated with Jingbai'an can bring better disease control effects and survival benefits to patients with leukemia and multiple myeloma, and clinical applications and exploration are worth further promotion.

However, due to the interruption of the original research medicine, Chinese patients once faced the urgent situation available to the non -white -free security. To this end, China Resources Shuanghe Pharmaceutical Co., Ltd. has developed the first domestic Baixian An Note after unrelenting efforts to break through the difficulties of crafts. —Solinshelbaiba An Note, which not only fills the gaps in domestic drugs, meets the patient's urgent treatment needs, breaks the monopoly of the original foreign research drugs, and the double cranes and white centered note. Here comes more high -quality treatment options.

In order to better guide clinical practice and benefit Chinese patients who need to accept hematopoietic stem cell transplantation, it also provides key pharmacokinetic data for Bai Lian'an injection, and initially evaluates its safety and effectiveness. The Children's Hospital launched a research on pharmacokinetics in children with Bai Xiannian injection in the transplantation of hematopoietic stem cell transplantation. Professor Sun Ning, the hospital, introduced the test plan.

The discussion session of the second half of the forum was chaired by Professor Jiang Erlie. Many participating experts put forward many valuable suggestions on the application of Bai'an in the transplantation of hematopoietic stem cells, and the choice of different pre -processing plans:

Professor Han Yun at Peking University First Hospital: The pre -processing plan before transplanting has been evolving continuously. It is not until the emergence of Bai Lian'an that the plan gradually fixes. Experience, Shuanghebai's nominarian injection and the original drugs reaches better biological consistency, and clinically can "use it" to quickly benefit from Chinese patients.

Professor Zhao Mingfeng, Tianjin First People's Hospital: Bai Lian'an's position in hematopoietic stem cell transplantation is almost irreplaceable, and the digestive tract of intravenous transmission drugs has a slight adverse response, and clinicians and patients are also willing to use this drug It is hoped that the study of pharmacokinetic characteristics of different adult patients can be carried out in the future to better guide clinical medication.

Professor Bai Jie, the Second Hospital of Tianjin Medical University: Bai Lian'an has an indispensable position in the pre -processing plan proposed in China in China. Therefore Multiple clinical pre -pharmacokinetics research and clinical research data helps to standardize different centers. Professor Gao Feng of the Affiliated Hospital of North China University of Technology: Bai Lian'an is currently fixed in clinical usage. It is hoped that subsequent research on drug concentration monitoring can be carried out to clarify its effective concentration range.

Professor Zhang Ye of the Affiliated Hospital of Jining Medical College: For patients with different conditions and different transplantation conditions, such as relapse/refractory patients, umbilical cord blood transplant patients, etc. Essence

Professor Jiang Erlie pointed out in the summary speech of the second half of the Summit Forum: "Bai Lian'an's clinical application has been for decades, and the application related issues are not new. , Especially at home, the data mostly came from abroad, and the characteristics of the drug metabolism of patients at home and abroad are significantly different. Therefore, foreign data cannot be copied. It is expected that domestic pharmaceutical companies will participate in more drug -based studies to make the treatment more refined. Hua, individualization. "

*This article is only used to provide scientific information to medical people, and does not represent the viewpoint of this platform

- END -